Literature DB >> 33552952

Mutational Landscape for Indian Hereditary Breast and Ovarian Cancer Cohort Suggests Need for Identifying Population Specific Genes and Biomarkers for Screening.

Mohammed Shaad N Kadri1, Komal M Patel1, Poonam A Bhargava1, Franky D Shah2, Nutan V Badgujar2, Bhoomi V Tarapara2, Prabhudas S Patel2, Mohammed Inayatullah Shaikh1, Krati Shah3, Apurva Patel2, Shashank Pandya2, Hemangini Vora2, Chaitanya G Joshi1, Madhvi N Joshi1.   

Abstract

BACKGROUND: Breast and ovarian cancers are the most prevalent cancers and one of the leading causes of death in Indian women. The healthcare burden of breast and ovarian cancers and the rise in mortality rate are worrying and stress the need for early detection and treatment.
METHODS: We performed amplicon sequencing of 144 cases who had breast/ovarian cancer disease (total 137 cases are patients and seven are tested for BRCA1/2 carrier) Using our custom designed gene panel consisting of 14 genes, that are associated with high to moderate risk of breast and ovarian cancers. Variants were called using Torrent Variant Caller and were annotated using ThermoFisher's Ion Reporter software. Classification of variants and their clinical significance were identified by searching the variants against ClinVar database.
RESULTS: From a total of 144 cases, we were able to detect 42 pathogenic mutations in [40/144] cases. Majority of pathogenic mutations (30/41) were detected in BRCA1 gene, while (7/41) pathogenic mutations were detected in BRCA2 gene, whereas, (2/41) pathogenic mutations were detected in TP53 gene and BRIP1, PALB2, and ATM genes respectively. So, BRCA genes contributed 88.09% of pathogenic mutations, whereas non-BRCA genes contributed 11.91% of pathogenic mutations. We were also able to detect 25 VUS which were predicted to be damaging by in silico prediction tools.
CONCLUSION: Early detection of cancers in the Indian population can be done by genetic screening using customized multi-gene panels. Indications of our findings show that in the Indian population, apart from the common BRCA genes, there are other genes that are also responsible for the disease. High frequency mutations detected in the study and variants of uncertain significance predicted to be damaging by in silico pathogenicity prediction tools can be potential biomarkers of hereditary breast and ovarian cancer in Indian HBOC patients.
Copyright © 2021 Kadri, Patel, Bhargava, Shah, Badgujar, Tarapara, Patel, Shaikh, Shah, Patel, Pandya, Vora, Joshi and Joshi.

Entities:  

Keywords:  BRCA1 and BRCA2; amplicon sequencing; customized multi-gene panel; genetic testing; hereditary breast and ovarian cancer; next generation sequencing; non-BRCA genes

Year:  2021        PMID: 33552952      PMCID: PMC7859489          DOI: 10.3389/fonc.2020.568786

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  22 in total

1.  Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.

Authors:  Andrea Desmond; Allison W Kurian; Michele Gabree; Meredith A Mills; Michael J Anderson; Yuya Kobayashi; Nora Horick; Shan Yang; Kristen M Shannon; Nadine Tung; James M Ford; Stephen E Lincoln; Leif W Ellisen
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

2.  The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim.

Authors:  R B Bar-Sade; A Kruglikova; B Modan; E Gak; G Hirsh-Yechezkel; L Theodor; I Novikov; R Gershoni-Baruch; S Risel; M Z Papa; G Ben-Baruch; E Friedman
Journal:  Hum Mol Genet       Date:  1998-05       Impact factor: 6.150

3.  A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients.

Authors:  Stephen E Lincoln; Yuya Kobayashi; Michael J Anderson; Shan Yang; Andrea J Desmond; Meredith A Mills; Geoffrey B Nilsen; Kevin B Jacobs; Federico A Monzon; Allison W Kurian; James M Ford; Leif W Ellisen
Journal:  J Mol Diagn       Date:  2015-07-22       Impact factor: 5.568

4.  Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.

Authors:  Jun Li; Huong Meeks; Bing-Jian Feng; Sue Healey; Heather Thorne; Igor Makunin; Jonathan Ellis; Ian Campbell; Melissa Southey; Gillian Mitchell; David Clouston; Judy Kirk; David Goldgar; Georgia Chenevix-Trench
Journal:  J Med Genet       Date:  2015-11-03       Impact factor: 6.318

5.  Meta-analysis of BRCA1 and BRCA2 penetrance.

Authors:  Sining Chen; Giovanni Parmigiani
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

6.  Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.

Authors:  Jaya Singh; Nishita Thota; Suhasini Singh; Shila Padhi; Puja Mohan; Shivani Deshwal; Soumit Sur; Mithua Ghosh; Amit Agarwal; Ramesh Sarin; Rosina Ahmed; Sachin Almel; Basumita Chakraborti; Vinod Raina; Praveen K DadiReddy; B K Smruti; Senthil Rajappa; Chandragouda Dodagoudar; Shyam Aggarwal; Manish Singhal; Ashish Joshi; Rajeev Kumar; Ajai Kumar; Deepak K Mishra; Neeraj Arora; Aarati Karaba; Satish Sankaran; Shanmukh Katragadda; Arunabha Ghosh; Vamsi Veeramachaneni; Ramesh Hariharan; Ashraf U Mannan
Journal:  Breast Cancer Res Treat       Date:  2018-02-22       Impact factor: 4.872

7.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

8.  Prevalence and impact of founder mutations in hereditary breast cancer in Latin America.

Authors:  Patricia Ashton-Prolla; Fernando Regla Vargas
Journal:  Genet Mol Biol       Date:  2014-03       Impact factor: 1.771

9.  The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Authors:  Marie Eliade; Jeremy Skrzypski; Amandine Baurand; Caroline Jacquot; Geoffrey Bertolone; Catherine Loustalot; Charles Coutant; France Guy; Pierre Fumoleau; Yannis Duffourd; Laurent Arnould; Alexandra Delignette; Marie-Martine Padéano; Côme Lepage; Géraldine Raichon-Patru; Axelle Boudrant; Marie-Christine Bône-Lépinoy; Anne-Laure Villing; Aurélie Charpin; Karine Peignaux; Sandy Chevrier; Frédérique Vegran; François Ghiringhelli; Romain Boidot; Nicolas Sevenet; Sarab Lizard; Laurence Faivre
Journal:  Oncotarget       Date:  2017-01-10

10.  The mutational constraint spectrum quantified from variation in 141,456 humans.

Authors:  Konrad J Karczewski; Laurent C Francioli; Grace Tiao; Beryl B Cummings; Jessica Alföldi; Qingbo Wang; Ryan L Collins; Kristen M Laricchia; Andrea Ganna; Daniel P Birnbaum; Laura D Gauthier; Harrison Brand; Matthew Solomonson; Nicholas A Watts; Daniel Rhodes; Moriel Singer-Berk; Eleina M England; Eleanor G Seaby; Jack A Kosmicki; Raymond K Walters; Katherine Tashman; Yossi Farjoun; Eric Banks; Timothy Poterba; Arcturus Wang; Cotton Seed; Nicola Whiffin; Jessica X Chong; Kaitlin E Samocha; Emma Pierce-Hoffman; Zachary Zappala; Anne H O'Donnell-Luria; Eric Vallabh Minikel; Ben Weisburd; Monkol Lek; James S Ware; Christopher Vittal; Irina M Armean; Louis Bergelson; Kristian Cibulskis; Kristen M Connolly; Miguel Covarrubias; Stacey Donnelly; Steven Ferriera; Stacey Gabriel; Jeff Gentry; Namrata Gupta; Thibault Jeandet; Diane Kaplan; Christopher Llanwarne; Ruchi Munshi; Sam Novod; Nikelle Petrillo; David Roazen; Valentin Ruano-Rubio; Andrea Saltzman; Molly Schleicher; Jose Soto; Kathleen Tibbetts; Charlotte Tolonen; Gordon Wade; Michael E Talkowski; Benjamin M Neale; Mark J Daly; Daniel G MacArthur
Journal:  Nature       Date:  2020-05-27       Impact factor: 69.504

View more
  1 in total

1.  Pathogenic Variant Profile of Hereditary Cancer Syndromes in a Vietnamese Cohort.

Authors:  Van Thuan Tran; Sao Trung Nguyen; Xuan Dung Pham; Thanh Hai Phan; Van Chu Nguyen; Huu Thinh Nguyen; Huu Phuc Nguyen; Phuong Thao Thi Doan; Tuan Anh Le; Bao Toan Nguyen; Thanh Xuan Jasmine; Duy Sinh Nguyen; Hong-Dang Luu Nguyen; Ngoc Mai Nguyen; Duy Xuan Do; Vu Uyen Tran; Hue Hanh Thi Nguyen; Minh Phong Le; Yen Nhi Nguyen; Thanh Thuy Thi Do; Dinh Kiet Truong; Hung Sang Tang; Minh-Duy Phan; Hoai-Nghia Nguyen; Hoa Giang; Lan N Tu
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.